You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model
SBC: Cytex Therapeutics, Inc. Topic: NIAMSAbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of user-friendly fluorescence based assays for marine toxins
SBC: SEATOX RESEARCH INC Topic: 113ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic Nitric Oxide Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDPROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Interactive technology for media literacy drug prevention in community groups
SBC: REAL PREVENTION LLC Topic: NIDAThe goals of this Phase II STTR are to evaluate the outcomes of REAL mediaan interactiveselfpacede learning substance use prevention media literacy curriculum and prepare it for marketing to community organizationsincluding our partnerHSubstance use increases in frequency and risk through mid adolescenceyet prevention interventions primarily target early useare time intensiveand are implemented in ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
AutoRegister: A system for enhancing the accuracy of tumor change detection
SBC: CORTICOMETRICS LLC Topic: 102PROJECT SUMMARY This project proposes to continue the development of AutoRegisterTMan integrated software based system for enhancing the accuracy of tumor change detectionThe intent of the system is to automate the alignment of a patient s brain scan with that of a prior scan such that subsequent offline tumor measurements do not have error introduced solely by differing slice orientationsWhile si ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases
SBC: Eyedesis Biosciences, LLC Topic: NPROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer
SBC: Mekanistic Therapeutics, LLC Topic: NCIPROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Personalized Neural Stem Cell Therapy for Cancer
SBC: Falcon Therapeutics, Inc. Topic: NCATSProject Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development Characterization and Commercialization of a Viably Frozen Patient Inclusive Hepatocellular Carcinoma Tumor Bank
SBC: Woodland Pharmaceuticals LLC Topic: 103Abstract Hepatocellular carcinoma HCC is a disease of growing incidence globally including in the US by per year With the recent success of anti viral therapies the etiology of HCC in the American population is projected to shift from viral HBV HCV hepatitis to primarily fatty liver disease in the near future Currently only one effective systemic therapy has been developed for HCC ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of PAR Pepducins as a Novel Antithrombotic Treatment
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBICoronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregation and secretion are key components of arterial thrombus formation Despite dual anti platelet therapy for ACS and percutaneous coronary interventions PCI many patients sustain a high incidence u ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health